PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
Authors
Keywords
-
Journal
VIRCHOWS ARCHIV
Volume 461, Issue 2, Pages 129-139
Publisher
Springer Nature
Online
2012-08-09
DOI
10.1007/s00428-012-1267-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABI3 ectopic expression reduces in vitro and in vivocell growth properties while inducing senescence
- (2011) Flavia RM Latini et al. BMC CANCER
- PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression
- (2011) Kevin Kalinsky et al. BREAST CANCER RESEARCH AND TREATMENT
- Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
- (2011) Sandrine Boyault et al. BREAST CANCER RESEARCH AND TREATMENT
- Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer
- (2011) E. Razis et al. BREAST CANCER RESEARCH AND TREATMENT
- Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
- (2011) S Fasanella et al. Diagnostic Pathology
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Diagnostic Value of Automated Her2 Evaluation in Breast Cancer
- (2011) Chiara Cantaloni et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
- (2011) Bing-He Xu et al. Chinese Journal of Cancer
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells
- (2010) Caroline Brünner-Kubath et al. BREAST CANCER RESEARCH AND TREATMENT
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
- (2010) J. Dupont Jensen et al. CLINICAL CANCER RESEARCH
- Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers
- (2010) Bhuvanesh Dave et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
- (2009) S. Gori et al. ANNALS OF ONCOLOGY
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- (2009) Teemu T. Junttila et al. CANCER CELL
- PIK3CA in Breast Carcinoma
- (2009) Angela Michelucci et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality
- (2009) Elena López-Knowles et al. INTERNATIONAL JOURNAL OF CANCER
- PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients
- (2008) Yuen-Liang Lai et al. ANNALS OF SURGICAL ONCOLOGY
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas
- (2008) Enrique Lerma et al. VIRCHOWS ARCHIV
- PIK3CAcancer mutations display gender and tissue specificity patterns
- (2007) Silvia Benvenuti et al. HUMAN MUTATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now